Table 3.
Current antiretroviral therapy during coronary event and at the last follow-up visit.
| Coronary event n (%) |
Last follow-up visita
n (%) |
P valueb | |
|---|---|---|---|
| Without treatment (n = 28) | 17 (20) | 11 (14) | 0.3 |
| PI-based regimen (n = 68) | 33 (41) | 35 (43) | 0.87 |
| PI (with an unfavorable lipid profile) | 22 (67) | 13 (37) | 0.028 |
| Indinavir/r | 7 (21) | 2 (6) | 0.13 |
| Lopinavir/r | 15 (45) | 10 (29) | 0.23 |
| Fosamprenavir/r | 0 | 1 (3) | 1 |
| PI (with a favorable lipid profile) | 11 (33) | 22 (63) | 0.028 |
| Saquinavir/r | 2 (6) | 0 | 0.45 |
| Atazanavir/r | 6 (18) | 11 (31) | 0.33 |
| Darunavir/r | 3 (9) | 11 (31) | 0.048 |
| NNRTI-based regimen (n = 57) | 26 (32) | 31 (38) | 0.51 |
| Nevirapine | 15 (58) | 14 (45) | 0.5 |
| Efavirenz | 11 (42) | 17 (55) | 0.5 |
| Other treatments (n = 10) | 6 (7) | 4 (5) | 0.74 |
| Without treatment | 0 | 5 (33) | 1 |
|
| |||
| Nucleoside reverse transcriptase inhibitor | |||
| Abacavir | 15 (52) | 14 (48) | 1 |
aMedian time (IQR) from the coronary event until the last follow-up visit (June 2011): 7 (4; 11) years.
b P values express intragroup differences between coronary event time and last visit (after event).
PI: protease inhibitors; NNRTI: nonnucleoside analog reverse-transcriptase inhibitors.